Title
Category
Credits
Event date
Cost
- Depression
- Delivery of Care
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
For patients with depressive disorders treated with pharmacotherapy, measurement-based care is effective in decreasing symptom severity, promoting remission, and improving medication adherence.
- Cognition
- Geriatric Psychiatry
- Primary Care
- Substance Use Disorders
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
When older patients present with cognitive decline, it is important to rule out any organic, mood-related, or substance-induced etiology, such as alcohol use disorder.
- Depression
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Closer monitoring of symptoms through measurement-based care and setting symptom remission as a goal can help improve outcomes for adults with depression.
- Hepatitis
- Medical Conditions
- Neuropsychiatric Disorders
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Increased screening for hepatitis C virus among people with serious mental illness is key to achieving global eradication of the virus.
- Eating Disorders
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Night eating syndrome is a condition that requires early identification and management, especially among adolescents who develop symptoms during the transition into adulthood.
- Psychotic Disorders
- Veterans and Military Issues
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Measurement-based care (MBC) can improve patient outcomes, but data on its use in psychosis are sparse. This study examined the use of patient-reported outcome measures in veterans with psychosis to identify candidate measures for psychosis-related MBC.
- Psychotic Disorders
- Substance Use Disorders
- COVID-19
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Identifying risk factors that predispose individuals to negative COVID-19 outcomes is important. The current study examined the association between substance use disorders, psychiatric diagnosis, and COVID-19–related clinical outcomes.
- Wilson Disease
- Genetics
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Due to Wilson disease myriad manifestations, its rarity, and its range of symptoms, differential diagnosis may be challenging, leading to delays in treatment. This Neuroscience Commentary reviews diagnostic acumen and the latest updates in the field.
- Alzheimer Disease
- Cognition
- Dementia
- Geriatric Psychiatry
- Neurology
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Among the most transformative Alzheimer Disease discoveries is the existence of biomarkers which can manifest decades before onset of disease-related dementia.
- Alzheimer Disease
- Cognition
- Dementia
- Geriatric Psychiatry
- Neurology
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Navigating the associated differential diagnosis in AD is essential as various causes of cognitive impairment require different treatment strategies.